RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own white blood cells, combined with an immunotherapy drug (pembrolizumab), for people with ovarian cancer that has returned. The vaccine targets a protein found on many ovarian cancer cells, training the immune system…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New drug combo trial hopes to tame tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like certain melanomas, ovarian, and uterine cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will t…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis early-phase trial tests two drugs, abemaciclib and olaparib, together in people with ovarian cancer that stopped responding to platinum-based chemotherapy. The main goal is to find the safest dose and understand side effects. About 42 participants will take part to see if th…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC